HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

N,N-dimethyl-4-anisidine (DMPA)

Subscribe to New Research on N,N-dimethyl-4-anisidine

Share|Follow on Twitter

Also Known As:

DMPA; N,N-dimethyl-para-anisidine

Networked: 221 relevant articles (20 outcomes, 63 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 41
- Amines: 1208
  - Aniline Compounds: 3
    - N,N-dimethyl-4-anisidine: 221

Experts

1.	Taneepanichskul, Surasak: 5 articles (04/2009 - 02/2003)
2.	Jain, John K: 4 articles (07/2007 - 09/2006)
3.	Curtis, Kathryn M: 3 articles (10/2009 - 05/2006)
4.	Morrison, Charles S: 3 articles (04/2009 - 09/2004)
5.	Schulz, K F: 3 articles (01/2008 - 01/2005)
6.	Lopez, L M: 3 articles (01/2008 - 01/2005)
7.	Grimes, D A: 3 articles (01/2008 - 01/2005)
8.	Richardson, Barbra A: 3 articles (03/2007 - 01/2004)
9.	d'Arcangues, C: 3 articles (01/2007 - 01/2005)
10.	Bonny, Andrea E: 3 articles (01/2006 - 04/2004)

Related Diseases

1.	Hemorrhage 03/01/2000 - "DMPA is a safe and effective long-acting contraceptive agent; clinical attention should be directed to its most common side effect, irregular bleeding. " 01/01/2006 - "Our findings indicate that vaginal bleeding due to DMPA can be successfully treated, leading to improvement in continuation rates." 01/01/2006 - "A total of 131 patients who reported vaginal bleeding while on DMPA were included in this study and 83 were treated with monophasic OCP. " 01/01/2006 - "In this study, we attempted to determine if treating DMPA-associated vaginal bleeding with monophasic oral contraceptive pills (OCP) raised continuation rates. " 06/01/2009 - "CONCLUSION: In spite of a similar prevalence of bleeding disturbances, the effects of DMPA and the LNG-IUS on the subendometrial microvascularisation differ." Order ALL the reference details at left...
2.	Endometrial Neoplasms (Endometrial Cancer) 05/01/1996 - " A WHO hospital-based study of the relationship between endometrial cancer and DMPA use found a protective effect of DMPA which appeared to be longterm and as great as that associated with OCs. " 01/01/1995 - " Its hematological parameters are good and some studies showed that DMPA does not increase the risk of development of cancer of the endometrium, ovaries, and cervix. " 12/01/2001 - "Data on DMPA have shown a number of noncontraceptive and therapeutic benefits, the most prominent of which is an 80% reduction in the risk of endometrial cancer. " 01/01/1995 - " Higher doses of DMPA treat endometrial cancer. " 01/01/1995 - " DMPA use lowers the risk of endometrial cancer, and this protective effect lasts for 8 years after cessation of use. " Order ALL the reference details at left...
3.	Pain (Aches) 08/01/1996 - " Only pain at menstruation was significantly greater in women in the OC group (because of the absence of regular flow in subjects in the DMPA group). " 08/01/2004 - "This study was done to see if pinching the skin, prior to injection of DMPA, would reduce the pain of the injection, as suggested by the gate theory. " 08/01/2005 - "The concentrated form of DMPA led to greater pain at the injection site than did the less concentrated form, but this did not lead to higher discontinuation rates among adolescents." 01/01/2007 - "In addition to providing effective contraception, DMPA may reduce sickle pain crises." 08/01/2005 - "A prospective, single-blinded, randomized trial was initiated to determine whether injection site pain differed in adolescents receiving two concentrations of 150 mg of depot medroxyprogesterone acetate (DMPA). " Order ALL the reference details at left...
4.	Endometriosis (Adenomyosis) 08/01/1996 - " It was concluded that, in selected women with highly symptomatic endometriosis, DMPA offers good analgesic results with tolerable side effects." 03/01/2006 - "Recently, a new lower dose of DMPA, administered as a subcutaneous injection, has been approved for use in the USA as a contraceptive and a treatment for pain associated with endometriosis. " 01/01/2006 - "METHODS: This multicentre, 18 month, evaluator-blinded, comparator-controlled trial randomized 300 women with laparoscopically diagnosed endometriosis to 6 month treatment with subcutaneous injection of 104 mg/0.65 ml DMPA (DMPA-SC 104) every 3 months or leuprolide (3.75 mg monthly or 11.25 mg every 3 months), with 12 months post-treatment follow-up. " 01/01/2009 - "CONCLUSION: Concerning pain relief, the therapeutic efficacy of the contraceptive implant Implanon is not inferior to that of DMPA in symptomatic endometriosis." 11/15/1982 - "In Canada depot medroxyprogesterone acetate (DMPA) (Depo-Provera, Upjohn Company of Canada) has been cleared for use in the management of endometriosis in the nonpregnant woman and for palliation of advanced endometrial cancer. " Order ALL the reference details at left...
5.	Amenorrhea 09/01/2006 - "Rates of amenorrhea at Month 12 (52-64% across studies) and Month 24 (71% in the 2-year trial) were comparable with those originally reported for DMPA-IM. " 08/01/2009 - "For DMPA use, the weighted prevalence of amenorrhea at successive 90-day periods was 12%, 25%, 37% and 46%. " 10/01/2007 - "CONCLUSIONS: The menopausal status in DMPA users in amenorrhea should be determined based on at least two consecutive high FSH evaluations, since, as shown here, 40.6% of the women with high FSH had a low FSH in the subsequent determination. " 09/01/2006 - "CONCLUSION: Clinical data show that the incidence of amenorrhea increases over time with the use of DMPA-SC 104." 12/01/2001 - "Minor side effects of both formulations include menstrual irregularities in the early months of treatment and amenorrhea with DMPA. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Medroxyprogesterone Acetate (Depo-Provera)
2.	CycloProvera
3.	Leuprolide (Lupron)
4.	Mefenamic Acid (Pontal)
5.	Zidovudine (Retrovir)
6.	Anti-Bacterial Agents (Antibiotics)
7.	valdecoxib (Bextra)
8.	Tranexamic Acid (AMCA)
9.	Testosterone (Sustanon)
10.	Nandrolone (Nortestosterone)

Related Therapies and Procedures

1.	Contraception (Birth Control)
2.	Injections
3.	Intrauterine Devices (Intrauterine Device)
4.	Condoms (Condom)
5.	Subcutaneous Injections

blog comments powered by Disqus

TREATMENT OPTIONS
for Hemorrhage,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 3107 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>